The history of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial introduction generated massive returns, the expiration of its exclusive rights opened the avenue to generic competitors, dramatically eroding sales. This poses a specific dilemma for drug manufacturers relying on similar blockbuster offer

The history of Viagra, and its developer copyright, presents a challenging case study for investors. Initially a blockbuster drug, yielding billions in revenue , its exclusivity period created a flood of generic competition , significantly impacting its dominance. While certain businesses may try here to capitalize on male sexual dysfunction, the e